Source - SMW
Shield Therapeutics said a clinical trial of its Feraccru treatment for anemia failed to meet the study's primary objectives. 

'We are surprised and disappointed by these top-line findings,' chief executive Carl Sterritt said.

'Feraccru has previously demonstrated positive efficacy and safety in patients, which led to it being approved in Europe where it continues to gain commercial traction.'

'We now await the full dataset in order to fully understand the study's outcome and define the next steps in our strategy.'


At 9:42am: (LON:STX) Shield Therapeutics Plc share price was -55p at 57.5p



Related Charts

Shield Therapeutics (STX)

-1.00p (-3.51%)
delayed 09:51AM